NICE winning drug price war21st December 2009
The National Institute for Health and Clinical Excellence has recommended that trabectedin can be used by the NHS to treat cancer patients, following a deal with its manufacturer.
The drug is used to treat soft tissue sarcoma, which affects around 2,000 people in Britain. It is a rare kind of cancer that targets muscle and tissue in the body.
Trabectedin damages cancer cells and prevents them spreading to other areas of the body.
The new deal by NICE with the Spanish manufacturer PharmaMar could result in the price of trabectedin to the NHS being reduced by 50%.
Over the course of 2009, two other manufacturers have reduced prices in order to secure the watchdog's approval.
NICE has approved the drug for use when other treatments have not worked or have caused side-effects, and where PharmaMar will pay for treatment with a fifth course of the drug, if it is required.
Dr Carole Longson, Health Technology Evaluation Centre Director at Nice said: "We are delighted the Independent Appraisal Committee has been able to recommend trabectedin in its draft guidance. It has certainly not been an easy decision to make; soft tissue sarcoma is a rare cancer and the evidence was limited."
"However, treatment options for this type of cancer are limited and in the last 20 years there have been no major developments to treat the advanced stages of this disease. Being able to recommend trabectedin for use on the NHS represents a step forward in the care of this group of patients who may have very few treatment options left."
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: NICE winning drug price war
Author: Jess Laurence
Article Id: 13574
Date Added: 21st Dec 2009